GLP-1 Side Effects: Which Drug Has the Fewest — and Why

The GI side effect problem

GI side effects are the primary reason patients stop GLP-1 therapy. Dropout rates attributable to adverse events in clinical trials:

• Semaglutide (STEP 1): 7.0% withdrew due to adverse events
• Tirzepatide (SURMOUNT-1, 15 mg): 9.2% withdrew due to adverse events

These are trial numbers — real-world discontinuation rates due to side effects are higher. Patient community surveys suggest 20–30% of new GLP-1 users experience side effects severe enough to pause or stop treatment within the first 3 months.

Understanding the side effect profile — and differences between drugs — helps with drug selection and side effect management.

Semaglutide (Wegovy 2.4 mg): Phase 3 trial data

From STEP 1 (68 weeks, 1,961 adults with obesity):

Key pattern: Nausea and vomiting are the dominant acute side effects, worst in the first 8–12 weeks. Constipation tends to be persistent rather than transient.

Tirzepatide (Zepbound/Mounjaro): Phase 3 trial data

From SURMOUNT-1 (72 weeks, 2,539 adults with obesity; 15 mg arm):

Key pattern: Lower nausea and vomiting rates than semaglutide at matched trial timepoints. Constipation is similar. Abdominal pain significantly lower than semaglutide.

Direct comparison: semaglutide vs tirzepatide

Caution: These trials used different patient populations and designs — direct numerical comparison has significant limitations. SURMOUNT-5 (direct head-to-head) was not primarily designed to assess tolerability differences, but general data trends are consistent with tirzepatide having a modestly better GI tolerability profile.

Liraglutide (Saxenda 3 mg): Phase 3 trial data

From SCALE trial (56 weeks, 3,731 adults with obesity):

Key pattern: Liraglutide's side effect profile is modestly lower than semaglutide (reflecting its lower efficacy — less drug activity means fewer effects). However, liraglutide requires daily injection vs once-weekly for semaglutide and tirzepatide, which is a practical drawback.

When side effects are worst: the timing pattern

Understanding when side effects occur helps patients prepare:

Nausea: Peaks 24–72 hours after each injection for the first 1–2 weeks at a new dose, then typically subsides as tolerance develops. For most patients, nausea at a new dose is noticeable for 1–2 weeks, then manageable by weeks 3–4 at that dose. It recurs with each dose escalation.

Constipation: Unlike nausea, constipation does not reliably improve with time. It tends to be a persistent feature of GLP-1 therapy at any dose. Active management (fibre, hydration, osmotic laxatives) is required.

Vomiting: Most commonly triggered by eating too quickly, eating too much, or eating high-fat foods when GLP-1-induced gastric slowing is active. Behavioural changes (eating slowly, smaller portions, avoiding fatty foods) significantly reduce vomiting frequency.

Side effect management: what actually works

For nausea: (full nausea management guide)

• Small, frequent meals rather than three large ones
• Eating slowly
• Ginger tea or ginger supplements
• Cold foods (cold reduces GI irritation)
• Anti-nausea medications (ondansetron, promethazine) for severe cases — prescribing varies
• Dose hold or reduction if severe
• Hydration (dehydration worsens nausea)

For vomiting:

• Avoid trigger foods (greasy, heavily spiced, high-fat)
• Eat half portions and wait before more
• Eat sitting upright; wait 30 minutes before lying down
• Avoid eating close to injection day

For constipation:

• Psyllium husk supplement (1–2 tsp daily in water)
• MiraLax/Macrogol (osmotic laxative) — safe for ongoing use
• Magnesium glycinate 200 mg at night
• Increase fluid intake
• Physical activity (walking increases GI motility)

For diarrhoea:

• Usually transient (first 2–3 weeks of each dose)
• BRAT-adjacent eating (bland, easily digested foods) during acute episodes
• Stay hydrated with electrolyte replacement
• Loperamide for short-term management if severe

Side effects unique to tirzepatide

Injection site reactions are somewhat more common with tirzepatide than semaglutide — redness, bruising, or bumping at injection sites. These resolve with rotation of injection sites.

Decreased appetite is listed as a side effect for tirzepatide, which may seem paradoxical (it is the intended effect), but the intensity of appetite suppression can be more pronounced than expected, particularly early in treatment.

Which drug to choose based on tolerability alone

If tolerability is the primary concern (not efficacy or cost):

Best tolerated: Tirzepatide modestly better than semaglutide for nausea, vomiting, and abdominal pain — see the tirzepatide vs semaglutide comparison for the full efficacy and tolerability picture. Constipation similar. For patients who have stopped semaglutide due to GI intolerance, tirzepatide is worth trying — the partial difference may be sufficient.

If both are intolerable: Saxenda (liraglutide 3 mg daily) has a modestly lower acute GI side effect profile, at the cost of lower efficacy and daily injection. It remains an option for patients who cannot tolerate weekly GLP-1 injections.

Dose management: Slower escalation is the most effective individual tolerability strategy. Extending time at any dose step reduces the frequency and severity of GI side effects substantially — more than switching drugs in most cases. See the Wegovy dose escalation schedule and Zepbound dose escalation schedule for exact titration protocols.

Summary

GLP-1 side effects are predominantly GI: nausea, vomiting, constipation, diarrhoea. Tirzepatide has modestly better tolerability than semaglutide for nausea, vomiting, and abdominal pain despite superior weight loss. Constipation is similar across all drugs and often persistent. Side effects peak during dose escalation and at each new dose step. Most patients tolerate GLP-1 therapy with appropriate behavioural management and slow titration; 7–20% discontinue in trials due to side effects.